J. Sharp, M. Lidsky, and J. Duffy, Clinical responses during gold therapy for rheumatoid arthritis. changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities, Arthritis & Rheumatism, vol.7, issue.5, pp.540-549, 1982.
DOI : 10.1001/jama.1962.03050340001001

G. Fiorino, C. Bonifacio, and M. Allocca, Bowel Damage as Assessed by the L??mann Index is Reversible on Anti-TNF Therapy for Crohn???s Disease, Journal of Crohn's and Colitis, vol.25, issue.8, pp.633-642, 2015.
DOI : 10.1097/00054725-200207000-00002

G. Fiorino, M. Morin, and S. Bonovas, Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn???s Disease and its Impact on Disease Outcome, Journal of Crohn's and Colitis, vol.doi, pp.10-1093, 2016.
DOI : 10.1038/ajg.2016.177

L. Maska, J. Anderson, and K. Michaud, Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment, Arthritis Care & Research, vol.39, issue.Suppl 39, pp.4-13, 2011.
DOI : 10.3109/03009740903447044

J. Fries, P. Spitz, R. Kraines, and H. Holman, Measurement of patient outcome in arthritis, Arthritis & Rheumatism, vol.33, issue.2, pp.137-182, 1980.
DOI : 10.1001/jama.1963.03060120024016

B. Bruce and J. Fries, The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation, J Rheumatol, vol.30, pp.167-78, 2003.

G. Stucki, A. Cieza, and S. Geyh, ICF Core Sets for rheumatoid arthritis, Journal of Rehabilitation Medicine, vol.36, issue.0, pp.87-93, 2004.
DOI : 10.1080/16501960410015470

C. Gebhardt, I. Kirchberger, G. Stucki, and A. Cieza, Validation of the comprehensive ICF Core Set for rheumatoid arthritis: the perspective of physicians, J Rehabil Med, vol.42, pp.780-788, 2010.

I. Kirchberger, A. Cieza, and G. Stucki, Validation of the Comprehensive ICF Core Set for rheumatoid arthritis: The perspective of psychologists, Psychology & Health, vol.44, issue.6, pp.639-59, 2008.
DOI : 10.1111/j.1365-2648.1994.tb01066.x

C. Allaart, Y. Goekoop-ruiterman, J. De-vries-bouwstra, F. Breedveld, and B. Dijkmans, Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study, Clin Exp Rheumatol, vol.24, issue.6, 2006.

L. Peyrin-biroulet, W. Reinisch, and J. Colombel, Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial, Gut, vol.140, issue.(Suppl 1), pp.88-95, 2014.
DOI : 10.1016/j.cgh.2012.03.026

L. Peyrin-biroulet, M. Ferrante, and F. Magro, Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease, Journal of Crohn's and Colitis, vol.50, issue.A-146, pp.477-83, 2011.
DOI : 10.1016/S0016-5107(99)80017-0

J. Colombel, E. Louis, L. Peyrin-biroulet, W. Sandborn, and R. Panaccione, Deep Remission: A New Concept?, Digestive Diseases, vol.358, issue.s3, pp.107-118, 2012.
DOI : 10.1056/NEJMoa0802743

URL : http://orbi.ulg.ac.be/bitstream/2268/138986/1/2012-Deep%20Remission%20-%20A%20New%20Concept-DigDis-Pr%c3%a9PA.pdf

J. Colombel, W. Reinisch, and G. Mantzaris, analysis, Alimentary Pharmacology & Therapeutics, vol.12, issue.Suppl. 1, pp.734-780, 2015.
DOI : 10.1016/j.cgh.2014.02.016

URL : https://hal.archives-ouvertes.fr/hal-01605208

L. Peyrin-biroulet, W. Sandborn, and B. Sands, Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, The American Journal of Gastroenterology, vol.107, issue.9, pp.1324-1362, 2015.
DOI : 10.1038/ajg.2012.117

URL : https://hal.archives-ouvertes.fr/hal-01191653

J. Colombel, N. Narula, and L. Peyrin-biroulet, Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases, Gastroenterology, vol.152, issue.2, pp.351-61, 2017.
DOI : 10.1053/j.gastro.2016.09.046

K. Machold, T. Stamm, and G. Eberl, Very recent onset arthritis? clinical, laboratory, and radiological findings during the first year of disease, J Rheumatol, vol.29, pp.2278-87, 2002.

C. Hitchon, C. Peschken, S. Shaikh, and H. El-gabalawy, Early Undifferentiated Arthritis, Rheumatic Disease Clinics of North America, vol.31, issue.4, pp.605-631, 2005.
DOI : 10.1016/j.rdc.2005.07.006

F. Arnett, S. Edworthy, and D. Bloch, The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis & Rheumatism, vol.143, issue.3, pp.315-339, 1988.
DOI : 10.1002/art.1780310302

R. Knevel, M. Schoels, and T. Huizinga, Current evidence for a strategic approach to the management of rheumatoid arthritis with diseasemodifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

T. Sokka, Drug management of early rheumatoid arthritis ??? 2008, Best Practice & Research Clinical Rheumatology, vol.23, issue.1, pp.93-102, 2009.
DOI : 10.1016/j.berh.2008.08.003

J. Singh, K. Saag, and S. Bridges, 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Arthritis Care & Research, vol.49, issue.Suppl, pp.1-25, 2015.
DOI : 10.1093/rheumatology/keg072

J. Smolen, C. Basset, S. Boers, and M. , Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease, Annals of the Rheumatic Diseases, vol.67, issue.Suppl 10, pp.1268-71, 2016.
DOI : 10.1002/art.39322

B. Combe, SP0183???2016 Update of The EULAR Recommendations for The Management of Early Arthritis, Annals of the Rheumatic Diseases, vol.75, issue.Suppl 2, p.44, 2016.
DOI : 10.1136/annrheumdis-2016-eular.6370

J. Van-nies, A. Krabben, and J. Schoones, What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review, Annals of the Rheumatic Diseases, vol.20, issue.S, pp.861-70, 2014.
DOI : 10.1093/rheumatology/keq424

J. Van-nies, E. Brouwer, and F. Van-gaalen, Clinics, Annals of the Rheumatic Diseases, vol.47, issue.8, pp.1295-301, 2013.
DOI : 10.1093/rheumatology/ken031

D. Aletaha, T. Neogi, and A. Silman, 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis & Rheumatism, vol.61, issue.Suppl 31, pp.2569-81, 2010.
DOI : 10.7326/0003-4819-124-8-199604150-00001

URL : https://hal.archives-ouvertes.fr/hal-01557559

S. Schreiber, J. Colombel, and R. Bloomfield, Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data, The American Journal of Gastroenterology, vol.102, issue.7, pp.1574-82, 2010.
DOI : 10.1016/S0140-6736(08)60304-9

P. Desreumaux, E. Brandt, and L. Gambiez, Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease, Gastroenterology, vol.113, issue.1, pp.118-144, 1997.
DOI : 10.1016/S0016-5085(97)70116-1

S. Kugathasan, L. Saubermann, and L. Smith, Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease, Gut, vol.56, issue.12, pp.1696-705, 2007.
DOI : 10.1136/gut.2006.116467

L. Peyrin-biroulet, V. Billioud, D. Haens, and G. , Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process, The American Journal of Gastroenterology, vol.12, issue.1, pp.1770-1776, 2012.
DOI : 10.1053/j.gastro.2005.12.019

V. Nell, K. Machold, G. Eberl, T. Stamm, M. Uffmann et al., Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis, Rheumatology, vol.43, issue.7, pp.906-920, 2004.
DOI : 10.1093/rheumatology/keh199

S. Danese, G. Fiorino, and J. Mary, Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn???s Disease: An IOIBD Initiative, Journal of Crohn's and Colitis, vol.39, issue.8, pp.601-607, 2015.
DOI : 10.1136/annrheumdis-2012-201777

URL : https://hal.archives-ouvertes.fr/hal-01668612

D. Haens, G. Baert, F. Van-assche, and G. , Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, The Lancet, vol.371, issue.9613, pp.660-667, 2008.
DOI : 10.1016/S0140-6736(08)60304-9

R. Khanna, B. Bressler, and B. Levesque, Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial, The Lancet, vol.386, issue.10006, pp.1825-1859, 2015.
DOI : 10.1016/S0140-6736(15)00068-9

J. Singh, D. Furst, and A. Bharat, 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care & Research, vol.42, issue.Suppl, pp.625-664, 2008.
DOI : 10.1093/rheumatology/keg072

L. Sizova, Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs, British Journal of Clinical Pharmacology, vol.3, issue.2
DOI : 10.7326/0003-4819-146-6-200703200-00005

S. Van-der-kooij, Y. Goekoop-ruiterman, and J. De-vries-bouwstra, Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.68, issue.6, pp.914-935, 2009.
DOI : 10.1136/ard.2008.092254

P. Emery, F. Breedveld, and S. Hall, Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial, The Lancet, vol.372, issue.9636, pp.375-82, 2008.
DOI : 10.1016/S0140-6736(08)61000-4

E. Keystone, D. Van-der-heijde, and D. Mason, Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Arthritis & Rheumatism, vol.340, issue.11, pp.3319-3348, 2008.
DOI : 10.7326/0003-4819-130-6-199903160-00004

L. Peyrin-biroulet, Disease-Modifying Anti-Inflammatory Bowel Disease Drugs (DMAIDs): The Missing Term in the Literature, The American Journal of Gastroenterology, vol.9, issue.5, pp.859-60, 2013.
DOI : 10.1056/NEJM200011303432202

URL : https://hal.archives-ouvertes.fr/hal-01701193

J. Cosnes, A. Bourrier, and D. Laharie, Early Administration of Azathioprine vs Conventional Management of Crohn's Disease: A Randomized Controlled Trial, Gastroenterology, vol.145, issue.4, pp.758-65, 2013.
DOI : 10.1053/j.gastro.2013.04.048

J. Pan-es, A. Bermejo, and F. , Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease, Gastroenterology, vol.145, issue.4, pp.766-74, 2013.
DOI : 10.1053/j.gastro.2013.06.009

L. Peyrin-biroulet and S. Danese, Early Combined Immunosuppression in Crohn???s Disease: Acting Rather Than REACTing, Gastroenterology, vol.150, issue.4, pp.1040-1041, 2016.
DOI : 10.1053/j.gastro.2016.02.056

URL : https://hal.archives-ouvertes.fr/hal-01666729

J. Torres, F. Caprioli, and K. Katsanos, Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases, Journal of Crohn's and Colitis, vol.19, issue.12, pp.660-667, 2016.
DOI : 10.1007/s00535-012-0603-2

G. Van-assche, A. Dignass, and W. Reinisch, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations, Journal of Crohn's and Colitis, vol.1, issue.Suppl 2, pp.63-101, 2010.
DOI : 10.1001/jama.299.14.1690

L. Peyrin-biroulet, G. Fiorino, A. Buisson, and S. Danese, First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?, Nature Reviews Gastroenterology & Hepatology, vol.60, issue.6, pp.345-51, 2013.
DOI : 10.1136/gutjnl-2011-300934

C. Zallot and L. Peyrin-biroulet, Clinical Risk Factors for Complicated Disease: How Reliable Are They?, Digestive Diseases, vol.59, issue.s3, pp.67-72, 2012.
DOI : 10.1136/gutjnl-2011-300049

M. Hetland, K. Stengaard-pedersen, and P. Junker, Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, Arthritis & Rheumatism, vol.39, issue.5, pp.1401-1410, 2006.
DOI : 10.1148/85.2.325

S. Lillegraven, F. Prince, and N. Shadick, Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort, Annals of the Rheumatic Diseases, vol.71, issue.5, pp.681-687, 2012.
DOI : 10.1136/ard.2011.154625

J. Torres, R. Boyapati, N. Kennedy, E. Louis, J. Colombel et al., Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease, Gastroenterology, vol.149, issue.7, pp.1716-1746, 2015.
DOI : 10.1053/j.gastro.2015.08.055

L. Peyrin-biroulet, J. Pan-es, and W. Sandborn, Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions, Clinical Gastroenterology and Hepatology, vol.14, issue.3, pp.348-54, 2016.
DOI : 10.1016/j.cgh.2015.06.001

URL : https://hal.archives-ouvertes.fr/hal-01668509

C. Siegel, C. Whitman, and B. Spiegel, Development of an index to define overall disease severity in IBD, Gut, vol.67, issue.2, pp.10-1136, 2016.
DOI : 10.1136/gutjnl-2016-312648